Local Coverage Determination (LCD):
MolDX: Breast Cancer Assay: Prosigna (L36380)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

## Contractor Information

<table>
<thead>
<tr>
<th>CONTRACTOR NAME</th>
<th>CONTRACT TYPE</th>
<th>CONTRACT NUMBER</th>
<th>JURISDICTION</th>
<th>STATE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01111 - MAC A</td>
<td>J - E</td>
<td>California - Entire State</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01112 - MAC B</td>
<td>J - E</td>
<td>California - Northern</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01182 - MAC B</td>
<td>J - E</td>
<td>California - Southern</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01211 - MAC A</td>
<td>J - E</td>
<td>American Samoa Guam Hawaii Northern Mariana Islands</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01212 - MAC B</td>
<td>J - E</td>
<td>American Samoa Guam Hawaii Northern Mariana Islands</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01311 - MAC A</td>
<td>J - E</td>
<td>Nevada</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01312 - MAC B</td>
<td>J - E</td>
<td>Nevada</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01911 - MAC A</td>
<td>J - E</td>
<td>American Samoa California - Entire State Guam Hawaii Nevada Northern Mariana Islands</td>
</tr>
</tbody>
</table>

## LCD Information

## Document Information

<table>
<thead>
<tr>
<th>LCD ID</th>
<th>Original Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Created on 02/06/2020. Page 1 of 7
**LCD Title**
MolDX: Breast Cancer Assay: Prosigna

**Proposed LCD in Comment Period**
N/A

**Source Proposed LCD**
DL36380

**AMA CPT / ADA CDT / AHA NUBC Copyright Statement**
CPT codes, descriptions and other data only are copyright 2019 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Current Dental Terminology © 2019 American Dental Association. All rights reserved.

Copyright © 2019, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at ub04@healthforum.com.

**CMS National Coverage Policy**
Title XVIII of the Social Security Act (SSA), §1862(a)(1)(A), states that no Medicare payment shall be made for
items or services that “are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.”

42 Code of Federal Regulations (CFR) §410.32 Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

This policy provides limited coverage of the Prosigna breast cancer gene signature assay to patients that meet the following criteria consistent with the FDA indications for use:

- Post-menopausal female either
  - ER+, lymph node-negative, stage I or II breast cancer; or
  - ER+, lymph node-positive (1-3 positive nodes), stage II breast cancer.

Claims for Prosigna testing will be denied when testing does not meet all of the above criteria.

Background

Women with early breast cancer and up to 3 locally positive lymph nodes whose tumor is estrogen-receptor positive will usually receive anti-hormonal therapy such as tamoxifen or aromatase inhibitors. U.S. (NCCN) and international (St. Gallen) guidelines predicate the decision for adjuvant chemotherapy on the size and grade of the breast cancer and other factors including genomic assays that provide additional information on risk of recurrence (Hernandez-Ava et al., 2013). According to a 2014 review, “Prognostic factors provide an indication of whether a patient needs subsequent therapy.” (Paoletti & Hayes, 2014). Similarly, another 2014 review article states, “Efforts should be focused on reducing chemotherapy in patients unlikely to benefit.” (Rampurwala et al., 2014). Accordingly, Medicare has covered breast cancer gene signature prognostic/predictive tests since 2006.

The PAM50 breast cancer gene signature test was developed in the late 1990s and initial studies showed a strong correlation with breast cancer recurrence and with complete pathologic response to neoadjuvant chemotherapy (Parker et al., 2009). While test results are reported on a scale of 1-100 as a Risk of Recurrence (ROR) score, the underlying algorithm is also able to classify cases into the luminal A and B, Her2neu, and triple-negative subtype classifications.

The Nanostring nCounter® nucleic acid analysis system replicates the PAM50 algorithm, as an FDA cleared kit, the Prosigna Breast Cancer Gene Signature Assay (FDA, 2013). The Prosigna package insert was most recently updated in January, 2015 (FDA, 2015) reflecting additional studies (Sestak et al., 2014). Notably, the Prosigna platform and the original PAM50 platform have a 0.997 correlation (Dowsett et al., 2013).

For the FDA, the Prosigna test was validated in a large population of post-menopausal, estrogen-receptor positive women based on 1,017 cases of the TransATAC study (Dowsett et al., 2013). The study showed a strong correlation with long-term breast cancer recurrence and added substantial additional prognostic information over a clinical
treatment score based on standard clinical variables. This study was replicated in an independent population, also on
the Prosigna test, using 1,620 samples from the ABCSG8 trial (Gnant, 2014). A separate analysis of these trials
validated prediction of distant recurrence in years 5-10 after initial diagnosis (Sestak et al., 2014) and has been
incorporated in the FDA labeling (FDA, 2015). The Prosigna test is issued as separate reports, consistent with FDA
review and labeling, for node-negative and node-positive (1-3 node) populations. Analytic performance, precision,
reproducibility, and analysis of the clinical validations are provided in the FDA labeling (FDA, 2013; FDA, 2015).

Clinical utility of this breast cancer gene signature has also been assessed. The study of Martin et al. (2015) showed
a 20% decision impact on decisions for or against adjuvant chemotherapy in an all-comers population of 200 new
cases of incident breast cancer, when Prosigna test information became available after all other clinical information
had been considered. The net rates of selecting adjuvant chemotherapy for low, intermediate, and high risk cases
was similar to that observed in a meta-analysis of Oncotype DX decision data (Carlson & Roth, 2013). Additional
support for the use of these test results in treatment decisions comes from Parker et al. (2009), in which there was a
strong association with neoadjuvant chemotherapy response. Low-scoring cases have a very low chance of complete
pathological response to neoadjuvant chemotherapy, while high-scoring cases approach a 50% chance of complete
pathological response. The same findings have been observed for other breast cancer gene signatures based on
prognostic algorithms (Chang et al., 2008).

Summary of Evidence

NA

Analysis of Evidence
(Rationale for Determination)

NA

General Information

Associated Information

Documentation Requirements

The patient's medical record must contain documentation that fully supports the medical necessity for services
included within this LCD (see Coverage Indications, Limitations, and/or Medical Necessity). This
documentation includes, but is not limited to, relevant medical history, physical examination, and results of pertinent
diagnostic tests or procedures.

Documentation supporting the medical necessity should be legible, maintained in the patient's medical record, and
must be made available to the MAC upon request.

This final LCD, effective 05/03/2016, combines JEA DL36320 into the JEB LCD so that both JEA and JEB contract
numbers will have the same final MCD LCD number.
No comments were received for comment period ending 12/07/2015.

Sources of Information

N/A

Bibliography


Revision History Information

<table>
<thead>
<tr>
<th>REVISION HISTORY DATE</th>
<th>REVISION HISTORY NUMBER</th>
<th>REVISION HISTORY EXPLANATION</th>
<th>REASON(S) FOR CHANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/01/2019</td>
<td>R4</td>
<td>The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD. At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a</td>
<td></td>
</tr>
</tbody>
</table>

• Other (The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.)

Created on 02/06/2020. Page 5 of 7
<table>
<thead>
<tr>
<th>REVISION HISTORY DATE</th>
<th>REVISION HISTORY NUMBER</th>
<th>REVISION HISTORY EXPLANATION</th>
<th>REASON(S) FOR CHANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/01/2019</td>
<td>R3</td>
<td>11/01/2019: This LCD is being revised in order to adhere to CMS requirements per chapter 13, section 13.5.1 of the Program Integrity Manual. There has been no change in coverage with this LCD revision. Regulations regarding billing and coding were removed from the <strong>CMS National Coverage Policy</strong> section of this LCD and placed in the related Billing and Coding: MolDX: Breast Cancer Assay: Prosigna Article A57363.</td>
<td>• Provider Education/Guidance</td>
</tr>
<tr>
<td>11/01/2019</td>
<td>R2</td>
<td>As required by CR 10901, all billing and coding information has been moved to the companion article, this article is linked to the LCD. At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.</td>
<td>• Revisions Due To Code Removal</td>
</tr>
<tr>
<td>01/01/2018</td>
<td>R1</td>
<td>2018 Annual CPT/HCPCS updates: Added 81520 to CPT/HCPCS codes section. 12/4/17: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.</td>
<td>• Creation of Uniform LCDs With Other MAC Jurisdiction  • Revisions Due To CPT/HCPCS Code Changes</td>
</tr>
</tbody>
</table>
**Associated Documents**

**Attachments**
N/A

**Related Local Coverage Documents**

Article(s)

LCD(s)
DL36320
- (MCD Archive Site)
DL36380
- (MCD Archive Site)

**Related National Coverage Documents**

N/A

**Public Version(s)**

Updated on 01/28/2020 with effective dates 11/01/2019 - N/A
Updated on 12/18/2019 with effective dates 11/01/2019 - N/A
Updated on 10/08/2019 with effective dates 11/01/2019 - N/A
Updated on 12/04/2017 with effective dates 01/01/2018 - 10/31/2019
Updated on 03/03/2016 with effective dates 05/03/2016 - N/A

**Keywords**

N/A